Navigation Links
FDA Issues Letter to Sunovion Pharmaceuticals, Claims Patient Brochures Made by Company to Support Its Respiratory Drug Brovana Mislead, Parker Waichman LLP Notes
Date:11/1/2013

New York, New York (PRWEB) November 01, 2013

Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs and medical devices, is noting that the U.S. Food and Drug Administration (FDA) has made allegations in a letter sent to Sunovion Pharmaceuticals on Oct. 24, 2013, that patient brochures made by the drug maker to support its respiratory drug Brovana are misleading in that they overstate the drug’s efficacy, make unsubstantiated claims, and minimize risks associated with the drug.

The FDA also alleges in its letter to Sunovion that the drug maker was promoting Brovana in a deceptive manner by downplaying references to the drug’s risks, which include a black-box warning of potential fatalities for some asthma patients, while highlighting in big, bold fonts the drug’s benefits. The brochures, the FDA letter further notes, also exaggerate the drug’s effectiveness by claiming it could help patients “resume their baseline activities of daily living.” Such claims were precluded by results of clinical studies, the letter notes, which found that Brovana produced an improvement of about 10 percent in the volume of air that patients can exhale during a forced breath.

“Drug makers need to be especially diligent when producing promotional material for the general public; keeping people informed with the best available information is always the proper solution,” says Gary Falkowitz, Managing Attorney at Parker Waichman LLP. “The FDA is doing exactly what they are supposed to. In view of that fact, we believe it is only appropriate for us to look at what is going on here a little more deeply.”

Parker Waichman is currently evaluating cases to determine whether a class action lawsuit is appropriate.

Marlborough, Mass.-based Sunovion Pharmaceuticals Inc., a unit of Osaka, Japan-based Dainippon Sumitomo Pharma Co. Ltd., received approval for its respiratory drug Brovana (generic name: arformoterol tartrate) by the FDA on Oct. 6, 2006, as noted on the FDA’s website, last updated on Feb. 19, 2012. Described as an “inhalation solution,” Brovana was approved for the treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, the FDA’s letter to Sunovion notes. Meant for long-term, twice daily (mornings and evenings) use, the drug is taken via a nebulizer only, says the letter.

If you or a loved one took the prescription drug Brovana, you may have valuable legal rights. To find out more about joining a Brovana class action lawsuit, please visit our website or contact one of our experienced class action lawyers today at 1(800)-LAW-INFO (1-800-529-4636).

Contact:
Parker Waichman LLP
Gary P. Falkowitz, Managing Attorney
1+ (800) LAW-INFO
1+ (800) 529-4636
http://www.yourlawyer.com

Read the full story at http://www.prweb.com/releases/fda_letter_brovana/11/prweb11294652.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. UCSF chancellor issues call-to-arms to patient advocates
2. Radiologists rank themselves as less than competent on health policy issues
3. Genetic abnormalities in benign or malignant tissues predict relapse of prostate cancer
4. FDA Issues Multiple Sclerosis Drug Alert
5. Quality of care, other issues may cause worse results in black prostate cancer surgery patients
6. U.S. Task Force Issues Blood Pressure Guidelines
7. Internists in Washington to discuss patient and professional issues in meetings on Capitol Hill
8. Cheaper drug could lead to serious eye issues
9. Insulite Labs announces the launch of the PCOS Inspiration Hour, a one hour virtual gathering place for women with PCOS and other women’s health issues to come together.
10. LawyersandSettlements.com Issues Report on Prostate Health Claim Lawsuits and Propecia Side Effect Litigation
11. What Men Should Know About Veins: Varicose Veins and Venous Disease are Real Medical Issues
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... (PRWEB) , ... ... ... For Immediate ... Polling Shows Young Women Seek Sex and Relationship Advice from ...
(Date:8/18/2017)... ... August 18, 2017 , ... Mediaplanet today announces the ... healthy lifestyles and highlighting the importance of proactive eye and ear health. The ... the latest innovations in hearing aid technology. , In this issue, the ...
(Date:8/18/2017)... WV (PRWEB) , ... August 18, 2017 , ... ... financial consulting services and asset protection assistance to communities in North-Central West Virginia, ... provide critical services to at-risk boys in the area. , The Chestnut Mountain ...
(Date:8/18/2017)... ... August 18, 2017 , ... Goss & Associates ... residential and commercial clients in the greater Houston region, is helping locally recognized ... the fight against cancer. , Founded by Tony and Amber Bender after losing ...
(Date:8/18/2017)... ... ... Overseer at The House of Yahweh in Abilene, Texas, has released a new publication this ... of the Savior whom the world calls “Mother Mary”. Yisrayl says when compared to what ... historical woman. , “The world bows, kisses the feet of, cries out to and ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... Aug. 15, 2017   Mostyn Law and Gulf Coast ... Houston, Texas . The Mostyn Law family has ... years. That is why Mostyn Law is partnering with ... to show its appreciation. Blood supplies are running low. ... short of hospital needs in August. That is why the blood ...
(Date:8/15/2017)... 15, 2017  AOTI Inc. announced today that its fully owned ... recently opened a New York City Office in Yonkers, ... unique Topical Wound Oxygen (TWO 2 ) homecare therapy. This new ... for Health Care (ACHC) under the company,s DMEPOS accreditation for Home/Durable ... Advanced ...
(Date:8/8/2017)... AVIV, Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: ... immunology, today reports its financial results for the second ... achievements during the second quarter 2017 and to date: ... multiple clinical development programs for the Company,s lead project, ... 3 pivotal study with BL-8040 as novel stem cell ...
Breaking Medicine Technology: